Back

Regeneron Highlights Growth and Pipeline Amid Competitive Biotech Landscape

lite News Desk 2 min read

At a glance

  • Regeneron reported $14.3 billion in 2025 revenue, a 1 % increase from 2024
  • Dupixent and Eylea HD sales showed strong growth in late 2025
  • Settlements allow Eylea biosimilars to enter the U.S. market in late 2026

Regeneron Pharmaceuticals, based in Westchester County, New York, has reported steady financial performance and continued investment in research as it navigates a changing biotechnology environment.

In 2025, Regeneron’s full-year revenues reached approximately $14.3 billion, reflecting a modest increase from the previous year. The company’s growth has been supported by key products, with Dupixent and Eylea HD contributing substantially to sales figures in the fourth quarter of 2025.

Global net sales of Dupixent rose by about 34 % in the last quarter of 2025, bringing full-year sales to $17.8 billion, an increase of 26 % over the prior year. U.S. net sales for Eylea HD increased by 66 % in the fourth quarter, while combined U.S. sales for Eylea HD and Eylea declined by 28 % to $1.1 billion for the same period.

Settlements reached in late 2025 with Celltrion, Alvotech, and Teva have set timelines for the introduction of Eylea biosimilars in the U.S. market. Celltrion’s Eydenzelt is scheduled for U.S. launch on December 31, 2026, and AVT06 from Alvotech and Teva may enter the market in the fourth quarter of 2026 or earlier under certain conditions.

What the numbers show

  • Regeneron’s 2025 revenue: $14.3 billion, up 1 % from 2024
  • Q4 2025 Dupixent global net sales: $4.9 billion, up 34 %
  • Q4 2025 U.S. Eylea HD sales: $506 million, up 66 %
  • Full-year 2025 Eylea HD U.S. sales: $1.6 billion, up 36 %
  • Combined U.S. Eylea HD and Eylea sales fell 27 % in 2025

Regeneron’s research and development activities were highlighted at the 2026 J.P. Morgan Healthcare Conference, where the company stated that its platform-driven approach has resulted in 14 internally discovered approvals over 15 years. This averages to about one major product approval each year.

For 2026, Regeneron has outlined plans to allocate approximately $6 billion to research and development and $7 billion to capital expenditures in the United States. These investments are intended to support ongoing manufacturing and research capabilities.

In March 2026, The Motley Fool stated that Regeneron’s growth is primarily supported by Dupixent and Eylea HD, with additional late-stage programs in areas such as hematology, immunology, and rare diseases. The company’s pipeline is positioned to address a range of therapeutic areas.

Industry reaction

In early 2026, Bank of America upgraded Regeneron’s stock rating to “Buy” and increased its price target to $860. The bank cited confidence in the performance of Eylea HD, ongoing Dupixent growth, and several upcoming product developments as reasons for its decision.

Industry coverage in March 2026 noted the importance of Regeneron’s expanding pipeline and the role of its leading products in driving recent sales growth. Institutional commentary has focused on the company’s ongoing investments and product launches as key factors in its competitive position.

* This article is based on publicly available information at the time of writing.

Sources and further reading

Note: This section is not provided in the feeds.

Related Articles

  1. L’Oréal reported €44.05 billion in sales for 2025, with a 20.2% operating margin. The company increased its stake in Galderma to 20%.

  2. HPE raised its fiscal 2026 EPS guidance to $2.25–$2.45 and projects networking revenue growth of 65–70%, according to company statements.

  3. Cracker Barrel reported a $24.6 million net loss in Q1 fiscal 2026, with same-store traffic down 8% after a logo change, according to company data.

  4. Nvidia reported $57.01 billion in Q3 FY2025 revenue, with data center sales reaching $51.2 billion, according to company data.

  5. A statement emphasizes the need for collaboration and caution in AI development, according to Hannah Fry. Concerns about overestimating capabilities persist.

More on Health

  1. Local temperatures have risen by about 2°C due to AI data centres, impacting over 340 million people, according to recent studies.

  2. A study describes Krause corpuscles in genital tissue, noting clitoral density is 15 times greater than in the penis, according to researchers.

  3. Engagement involved 2,658 participants and six partner organizations, according to reports. The initiative focuses on inclusive genomic research.

  4. The BBB warns of "ghost tapping" scams targeting tap-to-pay users. Reported losses reach $1,100. Use RFID-blocking wallets for protection.